Global pharmaceutical manufacturing companies Bora Pharmaceuticals and GSK have agreed to renew their manufacturing partnership for another five years in a new $250 million (AUD 353.8 million) contract.
In a recent statement, Bora said the deal expands the collaboration between the two global companies and enables GSK to access multiple sites within the Bora network, including an oral solid dose site in Minnesota.
GSK is the largest pharmaceutical partner at Bora’s Mississauga facility, which handles the manufacturing process for over 225 individual products.
Bora purchased the site from GSK in 2020 and has been using it to deliver end-to-end manufacturing services for more than 20 commercial product lines.
Medicines produced in this site treat a wide range of conditions, including HIV, malaria, and pneumonia, as well as depression and migraines. It also produces dermatological treatments for acne, eczema and psoriasis.
With the renewed contract, GSK will continue to rely on Bora’s manufacturing capabilities to ensure a steady supply of these important therapies to patients across the globe.
“Strong partnerships like this are foundational to the continued growth of Bora’s CDMO business,” said J.D. Mowery, president of Bora’s CDMO division. “GSK’s continued trust in Bora reflects our strong execution across development and commercial manufacturing and supports our momentum as we expand our role as a global CDMO of choice.”
Following integration into the Bora network, the Mississauga facility has expanded its technical capabilities and customer base.
The company attributed this growth to targeted investments in flexible manufacturing technologies. These investments have enabled the site to support 32 clients, advance 61 products and complete over 400 projects and development batches.
“Ultimately, partnerships are realised on the manufacturing floor,” said John Lawrie, VP of Operations at Bora’s Mississauga site. “Our teams, systems, and processes are ready to deliver on time in full consistently to support the continued manufacture of GSK’s medicines.”
“Reaching nearly a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We’re grateful for the opportunity to continue supporting GSK’s mission and the patients who rely on these therapies,” said Bobby Sheng, chairman of Bora Group and CEO of Bora.
